Discussion
cardiac and renal response, cardiac stage, MM
In this post hoc subgroup analysis of Asian patients enrolled in ANDROMEDA, a higher hematologic CR rate and deeper and more rapid hematologic responses were observed with D-VCd versus VCd; results were generally consistent across body weight subgroups. Improved MOD-PFS, MOD-EFS, and cardiac and renal response rates at 6 months were also observed in the Asian cohort, with improved MOD-PFS and 6-month organ response rates seen across body weight subgroups. In the Asian cohort, cardiac and renal response rates at 6 months were generally higher with D-VCd versus VCd, regardless of baseline cardiac stage. These results indicate that the addition of daratumumab to VCd elicits deeper responses and prolongs MOD-PFS and MOD-EFS compared with VCd alone in Asian patients. The efficacy results presented here for the Asian cohort overall and by baseline body weight are consistent with those from the global ANDROMEDA population [Of note, although the hematologic ORR and ≥ VGPR rates in the VCd arm of the ANDROMEDA Asian cohort (ORR, 93.5%; ≥ VGPR, 61.3%) were in line with those from other published reports for bortezomib-containing regimens in Asian patients (ORR, 66.2–90.0%; ≥ VGPR, 54.2–75.0%), a lower proportion of patients in the ANDROMEDA Asian cohort achieved hematologic CR with VCd (CR, 9.7%) compared to these other reports (CR, 36.1–60.0%) [D-VCd demonstrated an acceptable safety profile in Asian patients that was generally consistent with the global safety population from ANDROMEDA and the known safety profile of the individual components [There are several limitations of this post hoc analysis. The imbalance in cardiac stage between treatment groups in the Asian cohort may have impacted the magnitude of the efficacy differences observed between D-VCd and VCd in favor of the D-VCd group. Additionally, this analysis was limited by data immaturity and by the relatively low patient numbers in the Asian cohort.Results of this subgroup analysis complement those reported for the Asian subgroup analysis of COLUMBA in relapsed or refractory MM [The addition of DARA SC to VCd was superior to VCd alone in Asian patients, resulting in deeper and more rapid hematologic responses and improved organ responses. Treatment with D-VCd improved clinical outcomes, including MOD-PFS and MOD-EFS, versus VCd alone in Asian patients. Although this post hoc subgroup analysis was limited by data immaturity and a small sample size, efficacy and safety of D-VCd in Asian patients overall and of low body weight were generally consistent with those of the global ANDROMEDA population [